Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy helps boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy. (Ching-Hon Pui, MD)
St. Jude Children's Research Hospital closes survival gap for virtually all African-American and white children with cancer in a study that suggests equal access to care translates into an equal chance of a cure. (Dr. Ching-Hon Pui)
An international study found that bone marrow transplants are not the best option for some young patients with acute lymphoblastic leukemia (ALL) who fail to attain clinical remission after the initial weeks of intense chemotherapy known as induction therapy. (Dr. Ching-Hon Pui)
St. Jude Children’s Research Hospital physician is the recipient of the 2012 Pediatric Oncology Award.
The tiniest patients face the biggest odds when it comes to acute lymphoblastic leukemia. St. Jude clinicians and researchers work to change that scenario.
St. Jude Children’s Research Hospital investigators reported markedly improved survival of pediatric patients transplanted for high-risk leukemia regardless of donor; cite treatment advances and better donor selection.
St. Jude Children’s Research Hospital oncologist Ching-Hon Pui is the recipient of the 2011 Henry M. Stratton Medal for work that has advanced the research and treatment of pediatric leukemia
St. Jude boosts cure rates for older teens with acute lymphoblastic leukemia.
St. Jude Children’s Research Hospital pediatric oncologist Ching-Hon Pui, M.D., is the recipient of the 2011 Annual AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Research for contributions to childhood cancer research and treatment.
Research led by St. Jude Children’s Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer
Ching-Hon Pui, MD, of St. Jude Children's Research Hospital, is being honored with the Clinical Excellence Award at the fifth annual National Physician of the Year Awards, organized by Castle Connolly Medical Ltd.
St. Jude scientists identify a completely new and deadly subtype of leukemia that arises from early T-cell precursors. The discovery allows early detection and therapeutic intervention to improve the outcome for children with this form of drug-resistant leukemia.
Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully personalized chemotherapy regimen without cranial radiation, investigators at St. Jude Children's Research Hospital have found. Such radiation of the brain was once a standard ALL treatment to prevent recurrence of the leukemia in the central nervous system (CNS).
Scientists at St. Jude Children’s Research Hospital who represent the interdisciplinary team studying acute lymphoblastic leukemia (ALL) have been recognized by the American Association for Cancer Research (AACR) with the AACR Team Science Award.
The dramatic increase that has occurred in the cure rate for children with acute lymphoblastic leukemia (ALL) will be difficult to replicate in older patients without considerable additional research. In order to raise the survival rate of adolescents and adults with ALL, researchers will need a more thorough understanding of the biology of this form of leukemia, including the role that genes play in therapies.
The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to St. Jude investigators.
Investigators at St. Jude have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia, the most common cancer in children.
A small pilot program in the People's Republic of China has saved the lives of children who would otherwise have died from acute lymphoblastic leukemia (ALL) because of their family's inability to pay for care.
New report from St. Jude suggests that use of gene-based diagnosis and treatment, more effective use of existing drugs and adoption of emerging strategies will continue to boost ALL cure rate.
Partnerships between institutions from developed and underdeveloped countries could improve treatment of children with cancer even in areas of the world that have limited resources, according to St. Jude.
Accelerated approval of the drug clofarabine to treat relapsed or refractory pediatric acute lymphoblastic leukemia (ALL) shows the importance of offering children rapid access to new treatments through clinical trials, said investigators at St. Jude.
Improved risk classification for patients with acute lymphoblastic leukemia, more intensive chemotherapy for high risk patients and the use of a drug called dexamethasone, could one day permit physicians to omit irradiation as part of routine treatment.
A relatively small number of genes are linked to either resistance or sensitivity to four major cancer drugs used to treat acute lymphoblastic leukemia (ALL), suggesting that these genes are key to treatment outcome.
The city of Recife, Brazil, experienced a significant improvement in outcome among children treated for acute lymphoblastic leukemia (ALL) during the past decade, even though the community is resource-poor and most patient families are impoverished.
The cure rate for pediatric acute lymphoblastic leukemia (ALL) may continue to rise with improved use of conventional therapies. But even better therapies based on genetic and pharmacogenetic studies might one day push success rate to 100 percent.
When it comes to ALL treatment, survival rates for all children soar at St. Jude. A St. Jude team found that with equal access to effective therapy, both African-American and white patients could expect high cure rates.
A new study from St. Jude indicates that survivors of childhood acute lymphoblastic leukemia who have not received radiation treatment as part of their therapy have virtually the same long-term life experiences as the general population.
Survivors of childhood acute lymphoblastic leukemia (ALL) who have not received radiation treatment as part of their therapy have virtually the same long-term life experiences as the general population.
Investigators at St. Jude Children's Research Hospital have discovered numerous genes that alter their level of activity in characteristic patterns in response to specific chemotherapy treatments.